Fasudil fOr redUcing elopemeNt and Spatial Disorientation

NCT04793659 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Dementia

Interventions

DRUG: Oral Fasudil 90 mg/day
DRUG: Oral Fasudil 180 mg/day
DRUG: Oral Placebo

Sponsor

Woolsey Pharmaceuticals